Stock ORIC ORIC PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		5-day change 1st Jan Change
9.6 USD -0.10% Intraday chart for ORIC Pharmaceuticals, Inc. +2.89% +4.35%
May. 06 ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 15 ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
GL
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
AQ
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer
MT
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
GL
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
CI
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
GL
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting
CI
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GL
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
GL
JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating
MT
HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating
MT
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to S&P Biotechnology Select Industry Index
CI
Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating
MT
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
GL
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Oric Pharmaceuticals Insider Sold Shares Worth $648,380, According to a Recent SEC Filing
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ORIC Stock
  4. News ORIC Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW